[Biological regulation of copper and selective removal of copper: therapy for Wilson disease and its molecular mechanism].
Copper (Cu) is an essential trace element and constitutes the active center of the redox Cu enzymes such as Cu, Zn-superoxide dismutase (Cu, Zn-SOD), ceruloplasmin and cytochrome c oxidase. Among hereditary diseases due to a defect in the metabolism of Cu, Menkes disease (caused by a Cu deficiency) and Wilson disease (caused by the excessive accumulation of Cu) have been shown to be caused by the mutation of genes encoding Cu-binding ATPase for the efflux of Cu, ATP7A and ATP7B, respectively. Following the identification of these causative genes, intracellular Cu transporters (Cu chaperones) specific for the Golgi apparatus, mitochondria and Cu, Zn-SOD were discovered, and these findings have facilitated the study of the underlying mechanisms of the biological regulation of Cu. Apart from these physiological and biochemical studies, toxicological studies have elucidated the underlying mechanisms of the occurrence of acute hepatitis caused by the accumulation of Cu accumulating in the liver of an animal model for Wilson disease, LEC rats. In these toxicological studies, two biological aspects of metallothionein (MT), i.e., antioxidant and prooxidant depending on the Cu/Zn ratio in Cu-containing MT have been proposed. The present article overviews the recent findings on the biological regulation of Cu and on the toxicological aspect of Cu. It is known that Cu forms a stable ternary complex with molybdenum and sulfur under reductive conditions in the body. On the basis of this observation, tetrathiomolybdate (TTM) has been applied to remove Cu from the liver of Long-Evans rats with a cinnamon-like coat color (LEC) rats. Precise mechanisms underlying the complex formation between Cu bound to MT and TTM were presented, and an appropriate protocol for the chelation therapy was also proposed together with the mechanisms underlying the occurrence of side-effects.
Suzuki
K T
KT
Faculty of Pharmaceutical Sciences, Chiba University, Japan.
Ogura
Y
Y
D000251:Adenosine Triphosphatases; D000818:Animals; D002352:Carrier Proteins; D027682:Cation Transport Proteins; D002614:Chelating Agents / Q000627:therapeutic use; D003300:Copper / Q000378:metabolism*; D000073840:Copper-Transporting ATPases; D004195:Disease Models, Animal; D006527:Hepatolenticular Degeneration / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D008099:Liver / Q000378:metabolism; D008668:Metallothionein; D008982:Molybdenum / Q000009:adverse effects / Q000627:therapeutic use; D051381:Rats; D020332:Rats, Inbred LEC; D011993:Recombinant Fusion Proteins
D002352:Carrier Proteins; D027682:Cation Transport Proteins; D002614:Chelating Agents; D011993:Recombinant Fusion Proteins; D003300:Copper; D008982:Molybdenum; D008668:Metallothionein; C020809:tetrathiomolybdate; D000251:Adenosine Triphosphatases; C081184:ATP7A protein, human; C000612464:ATP7B protein, human; C486202:Atp7a protein, rat; D000073840:Copper-Transporting ATPases